UroGen Pharma (URGN) Tops Q2 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. DASH
9. MA
10. FND

Go back to UroGen Pharma (URGN) Tops Q2 EPS by 10c

 UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

August 4, 2021 8:00 AM EDT

Strong Jelmyto® net product revenue of $13.0 million for the second quarter of 2021, representing more than 70% growth over the first quarter of 2021 Nearly 100 global centers activated for Phase 3 landmark ATLAS trial with lead pipeline candidate, UGN-102 Commenced Jelmyto geographic expansion efforts with Neopharm license in Israel Conference call and webcast to be held today at 8:30 AM ET

PRINCETON, N.J.,--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty... More